Privo Technologies, Inc. Receives $2.5 Million from the National Cancer Institute for Intraoperative Treatment of Solid Tumors

PEABODY, Mass., February 25, 2022 /PRNewswire/ — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical-stage biopharmaceutical company focused on optimizing advanced oncology treatments, today announced that it has received $2.5M grant as part of the National Cancer Institute‘s Notice of Special Interest announcement.

The award supports the first-in-man clinical study of Privo’s PRV211 intraoperative cancer treatment. It is used for all solid tumors to remove any remaining cancer cells after surgical resection. Intraoperative treatment would be applied to the tumor bed immediately after tumor resection to remove micrometastases and treat nearby lymph nodes. PRV211 is a sterile derivative of PRV nano-engineered platform technology that safely and effectively delivers locoregional cancer treatments.

“Privo Technologies is grateful for NCI’s continued support in the development of the PRV platform,” said Manijeh GoldbergPhD, CEO of Privo Technologies, Inc. “Privo Technologies seeks to transform the standard of care for the treatment of solid tumors. Surgeons must strike a difficult balance: cutting too much and damaging functionality, removing too little and risking leaving tumor cells behind. “

The clinical trial will initially enroll patients with advanced head and neck cancer and then enroll patients with other solid tumors. Privo expects to open enrollment for this study in 2022.

About Privo TechnologiesInc.
Privo Technologies, Inc. (Privo) is a Phase 3 clinical-stage biopharmaceutical company committed to the development of novel therapies that have the potential to transform the standard of care for the treatment of solid tumors by providing safer and more effective alternatives. Privo is headquartered in Peabody (Massachusetts) and raised more than $16M to date in non-dilutive financing.

Privo’s lead asset, PRV111, has been shown to be effective in patients with head and neck cancer at multiple hospitals across the United States in a Phase I/II clinical study of safety and efficacy, dramatically reducing tumor volume without any systemic toxicity. For more information about Privo Technologies, Inc., please visit

About the National Cancer Institute (NCI)
The NCI leads the National Cancer Program and NIH efforts to dramatically reduce cancer prevalence and improve the lives of cancer patients and their families through research in cancer prevention and biology, the development of new interventions and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at or call the NCI contact center, the Cancer Information Service, at 1-800-4-CANCER ( 1-800-422-6237).

Quote See original content to download multimedia: -of -solid-tumors-301490290.html

SOURCE Privo Technologies

Comments are closed.